Iterum Therapeutics Director Dunne Buys 15,000 Shares at $0.72/Share on Aug 8.

Iterum Therapeutics plc (ITRM) announced that Director Michael W. Dunne acquired 15,000 shares at a price of $0.72 per share on August 8, 2025.

Dublin, Ireland — July 02, 2025 — Director Michael W. Dunne of Iterum Therapeutics plc (ITRM) has acquired 15,000 shares of the company at a price of $0.72 per share on August 8, 2025, according to a recent SEC Form 4 filing [1]. This transaction was made pursuant to a contract, instruction, or written plan for the purchase of equity securities, which satisfies the affirmative defense conditions of Rule 10b5-1(c) [1].

The acquisition follows a period of financial challenges for the company, as it reported a net loss of $6.51 million for the second quarter and $11.4 million for the six months ended June 30, 2025. The company's basic and diluted loss per share from continuing operations for the second quarter was $0.16, compared to $0.3 a year ago. For the six months, the basic and diluted loss per share was $0.31, compared to $0.76 a year ago [2].

Despite these losses, the company has been making progress in its pipeline. Iterum Therapeutics is expected to launch its oral antibiotic ORLYNVAH™ for uncomplicated urinary tract infections (uUTIs) in August 2025. The company has also entered into a partnership with EVERSANA Life Science Services, LLC for the commercialization of ORLYNVAH™ in the U.S. [3].

The acquisition of shares by Dunne, a 10% owner and director of the company, may indicate confidence in the company's future prospects, particularly given the upcoming launch of ORLYNVAH™. However, investors should also consider the company's recent financial performance and the competitive landscape in the antibiotic market.

References:
[1] https://www.sec.gov/Archives/edgar/data/1659323/000095017025106908/xslF345X05/ownership.xml
[2] https://www.marketscreener.com/news/iterum-therapeutics-plc-reports-earnings-results-for-the-second-quarter-and-six-months-ended-june-30-ce7c5ed8dc8ff626
[3] https://www.globenewswire.com/news-release/2025/08/05/3127171/0/en/Iterum-Therapeutics-Reports-Second-Quarter-2025-Financial-Results.html